Table 1.
Characteristics of DRibble preparations
| Antigensa | DAMPs | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient ID | Tumor # | # vac given | Tumor Cell Eq/vaccine | ∝g Protein/vaccine | P62 | NPM1 | KPNA2 | LDHB | ENO1 | PKM2 | HSP90 | HSP70 | CALR |
| Patient 2 | LT80 | 2 | 1.32E + 07 | 730 | ++ | +++ | ND | ND | +++ | ND | + | + | +++ |
| Patient 3 | LT79 | 3 | 1.65E + 07 | 125 | + | ND | ND | ND | +++ | ND | ND | +++ | + |
| Patient 5 | LT84 | 4 | 2.10E + 07 | 560 | +++ | + | ND | +++ | + | + | ND | +++ | + |
| Patient 6 | LT96 | 2 | 4.00E + 07 | 480 | +++ | +++ | + | ND | +++ | +++ | + | +++ | +++ |
DRibble vaccine was produced from autologous tumor and protein content was determined by the bicinchoninic acid assay (BCA). Proteins were identified by Western Blot and assigned plus symbols based on intensity of the blot (NPM1 nucleophosmin, KPNA2 karyopherin alpha 2, LDHB lactate dehydrogenase B, ENO1 enolase 1); PKM2 pyruvate kinase isozymes M1/M2, HSP Heat-shock protein, CALR Calreticulin. ND: Not Determined. aAntigens detected by Western blot